# A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

> **NCT07030907** · PHASE1 · RECRUITING · sponsor: **Outpace Bio, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Ovarian Cancer Recurrent
- Ovarian Cancer
- Platinum Resistant Ovarian Cancer

## Interventions

- **BIOLOGICAL:** OPB-101

## Key facts

- **NCT ID:** NCT07030907
- **Lead sponsor:** Outpace Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-16
- **Primary completion:** 2028-05-15
- **Final completion:** 2030-05-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07030907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07030907, "A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07030907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*